Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.71 and traded as low as $1.38. Akari Therapeutics shares last traded at $1.46, with a volume of 18,126 shares.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on Akari Therapeutics in a research note on Wednesday. They issued a “sell” rating on the stock.
Read Our Latest Stock Report on AKTX
Akari Therapeutics Stock Performance
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
See Also
- Five stocks we like better than Akari Therapeutics
- Differences Between Momentum Investing and Long Term Investing
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to SellÂ
- Health Care Stocks Explained: Why You Might Want to Invest
- Top 3 Beverage Stocks Pouring Out Profits
- Consumer Staples Stocks, Explained
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
